This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neal, B. Search for Related Content PubMed PubMed Citation Articles by Neal, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Social Bookmarking                         What's this?

Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease

Bruce Neal

Institute for International Health, 144 Burren Street, PO Box 576, Newtown, NSW 2042, Australia, bneal{at}iih.usyd.edu.au

Introduction

Among individuals with a history of myocardial infarction (MI), higher levels of blood pressure (BP) are associated with increased long-term risks of death from coronary heart disease. Treatment with a BPlowering regimen, based on omapatrilat may result in greater clinical benefits than treatment with a regimen based on a regular angiotensin-converting enzyme (ACE) inhibitor because of more favourable effects on the renin-angiotensin-aldosterone system.

Methods

Seven hundred and twenty-three clinically stable patients with a history of MI or unstable angina, and a mean entry BP of 134/77 mmHg, were randomised to six months treatment with omapatrilat 40 mg, omapatrilat 20 mg, or matching placebo.

Results

After six months, mean BP levels (systolic/diastolic) in the omapatrilat 40 mg group were reduced by 4.3/ 2.9 mmHg (95% confidence interval 1.3 to 7.2/1.2 to 4.6). Mean BP levels in the omapatrilat 20 mg group were reduced by 4.6/1.0 mmHg (1.6 to 7.6/—0.7 to 2.6) in comparison with the placebo group. Both doses of omapatrilat also produced significant decreases in plasma ACE activity and significant increases in levels of plasma renin activity, atrial natriuretic peptide, endothelin and homocysteine (p<0.05 for all). Premature discontinuations were more frequent with omapatrilat than with placebo (p<0.001 for 20 mg and 40 mg).

Conclusions

Omapatrilat produced changes in BP, neurohormone and biochemical parameters that were similar for the two doses. The long-term clinical implications of the observed effects are uncertain and a large-scale randomised trial would be required to reliably establish the effects of omapatrilat on the risks of major vascular disease events among patients with coronary heart disease.

Key Words: blood pressure • drugs • trials • hormones • coronary disease

References

• Flack J., Neaton J., Grimm R. et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995;92:2437-45.[Abstract/Free Full Text]
• Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.[Web of Science][Medline] [Order article via Infotrieve]
• Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356: 1955-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Burnett Jr J. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999;17:S37-S43.
• Rouleau J., Pfeffer M., Stewart D. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;19(356):615-20.
• McClean D., Ikram H., Garlick A., Richards A., Nicholls M., Crozier I. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36(2):479-86.[Abstract/Free Full Text]
• PACIFIC Study Group. Dose-dependent effects of folic acid on plasma homocysteine in a randomised controlled trial conducted among 723 individuals with coronary heart disease. Eur Heart J 2002;23:1509-15.[Abstract/Free Full Text]
• YandleT, Espiner E., Nicholls M., Duff H. Radioimmunoassay and characterisation of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab 1986;61:71-8.
• Yandle T., Richards A., Gilbert A., Fisher S., Holmes S., Espiner E. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76: 832-8.[Abstract]
• Goldstein D., Feurstein G., Izzo J., Kopin I., Keiser H. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man.Life Sci 1981;28:467-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hunt P., Richards A., Nicholls M., Yandle T., Doughty R., Espiner E. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-96.[CrossRef][Medline] [Order article via Infotrieve]
• Frantzen F., Faaren A.,Alfhein I., Nordhei A. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998;44:311-16.[Abstract/Free Full Text]
• Miller S., Dykes D., Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 1988;16:1215.[Free Full Text]
• Dunn P., Espiner E. Outpatient screening tests for primary aldosteronism. Australia NZ J Med 1976;6:131-5.
• Nicholls M., Espiner E.A sensitive rapid immuno assay for angiotensin II. NZ Med J 1976;83:399-403.[Web of Science][Medline] [Order article via Infotrieve]
• Lun S., Espiner E., Nicholls M., Yandle T. A direct radioimmunoassay for aldosterone in plasma. Clin Chem 1983;29:268-71.[Abstract/Free Full Text]
• Yandle T.,Richards A., Smith M., Charles C., Livesey J.,Espiner E. Assay of endopeptidase 24.11 (EC 3.4.24.11) activity in human plasma.Application to in vivo studies of endopeptidase inhibitors. Clin Chem 1992;38:1785-91.[Abstract/Free Full Text]
• Richards A., Nicholls M., Yandle T. et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neuro-hormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.[Abstract/Free Full Text]
• Wilcken D., Wang X., Sim S., McCredie M. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C 677 T mutation. Arterioscler Thromb Vasc Biol 1996;16:878-82.[Abstract/Free Full Text]
• Wilcken D., Wang X.,Adachi T. et al. Relationship between homocysteine and superoxide dismutase in homocystinuria: possible relevance to cardiovascular risk. Arterioscler Thromb Vasc Biol 2000;20:1199-202.[Abstract/Free Full Text]
• MacMahon S., Sharpe N., Gamble G. et al. Randomised, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J Am Coll Cardiol 2000;36:438-43.[Abstract/Free Full Text]
• Pesarin F. Permutation Testing of Multidimensional Hypothesis by nonparametric combination of dependent tests. Padova: Cleup Editrice; 1999.
• Davidian M., Giltinan D. Nonlinear models for repeated measurement data. London: Chapman & Hall; 1995.
• Weber M. Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999;12: 139S-147S.[Web of Science][Medline] [Order article via Infotrieve]
• HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEnglJMed 2000;342:145-53.[Abstract/Free Full Text]
• Messerli F., Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356:608-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Brown N., Vaughan D. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.[Abstract/Free Full Text]
• Richards A., Wittert G., Espiner E., Yandle T., Ikram H., Frampton C. Effect of inhibition of endopeptidase 24.11 on response to angiotensin II in human volunteers. Circ Res 1992;71:1501-07.[Abstract/Free Full Text]
• OgiharaT., Rakugi H., Masuo K.,Yu H., Nagano M., Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7: 943-7.[Web of Science][Medline] [Order article via Infotrieve]
• Bevan E., Connell J., Doyle J. et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-13.[Web of Science][Medline] [Order article via Infotrieve]
• Uemasu J., Matsumoto H., Kitano M., Kawasaki H. Suppression of plasma endothelin-1 level by alpha-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men. Life Sci 1993;53:969-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ferro C., Spratt J., Haynes W., Webb D. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-30.[Abstract/Free Full Text]
• Ando S., Rahman M., Butler G., Senn B., Floras J. Comparison of candoxatril and atrial natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26:1160-6.[Abstract/Free Full Text]
• Brattstrom L.,Wilcken D. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 4, 270-276 (2002)
DOI: 10.3317/jraas.2002.049


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neal, B. Search for Related Content PubMed PubMed Citation Articles by Neal, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Social Bookmarking                         What's this?